Does rivaroxaban prevent major ischemic or hemorrhagic events compared to apixaban in Medicare beneficiaries 65 years or older with atrial fibrillation?
In older Medicare patients with atrial fibrillation, rivaroxaban is associated with a higher risk of major ischemic or hemorrhagic events compared to apixaban.
Among Medicare beneficiaries 65 years or older with atrial fibrillation, treatment with rivaroxaban compared with apixaban was associated with a significantly increased risk of major ischemic or hemorrhagic events.
Ray et al. (Tue,) studied this question.